Pioneering software helps companies manage risks and opportunities through effective and efficient sustainability data capture, analysis and reporting NEW YORK, May 28, 2025 /PRNewswire/ -- Broadridge Financial Solutions, Inc. (NYSE: BR) a global Fintech leader, has joined forces with Novisto, a pioneer of enterprise sustainability software, to introduce an advanced sustainability data management and reporting platform for companies worldwide. Servicing clients in over 100 countries, Broadridge is at the fo ...

AvePoint (AVPT) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants James Arestia - VP - Investor RelationsTianyi Jiang - Co-Founder, CEO & DirectorJim Caci - Chief Financial OfficerJoe Vandrick - Associate Director - Equity ResearchJason Ader - Co-Group Head - Technology, Media & CommunicationsNehal Chokshi - Managing DirectorChirag Ved - Vice PresidentCole Erskine - Vice President - Equity ResearchBrett Knoblauch - Managing Director Operator Good day, and welcome to the Airfind Inc. First ...

Financial Data and Key Metrics Changes - Revenue for Q1 2025 increased to $4.2 million from $3.8 million in Q1 2024, primarily due to higher milestone revenue from GENmAb's clinical program [24] - Operating expenses decreased to $23 million from $26.4 million year-over-year, with R&D expenses down to $12.6 million from $14.6 million [25] - Net loss for Q1 2025 was $18.2 million or $0.17 per share, compared to a net loss of $19 million or $0.19 per share in Q1 2024 [26] Business Line Data and Key Metrics Changes - The number of active partners grew to 95, with new deals signed with Harvard's Weiss Institute, Takis Biotech, and Orion Corporation [9] - Total active programs increased to 378, with 33 active clinical programs and approved products as of the end of Q1 [10][11] - The company expects 5 to 7 new entries into clinical development for the year [11] Market Data and Key Metrics Changes - The exploration partner access program was launched, allowing partners to purchase exploration instruments for their labs, indicating a strategic move to enhance partner offerings [7][15] - The company anticipates that the exploration program will create new revenue streams and enhance partner workflows [21][46] Company Strategy and Development Direction - The company remains focused on driving innovation in drug discovery and enhancing its technology offerings [7][8] - The launch of the exploration partner access program is seen as a strategic enhancement to the existing offerings, aimed at creating long-term value for stakeholders [22] - The company is committed to growing its business with a focus on value creation and long-term profitability [22] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the strong start to 2025, with continued deal flow and a growing pipeline of partnered programs [6] - The company noted that the FDA's recent announcement regarding animal testing could streamline the entry of antibody-based medicines into the clinic, potentially benefiting the industry [68] Other Important Information - The company implemented a reduction in force in early February, resulting in an additional cash outlay of approximately $1 million in Q1, but expects lower expenses going forward [27] - The guidance for 2025 revenue remains between $20 million and $25 million, excluding contributions from the exploration program [28] Q&A Session Summary Question: What trends contributed to the strong number of program starts this quarter? - Management attributed the strong program starts to continued innovation and the launch of new technologies, with existing partners also starting new programs [32] Question: Is the exploration platform exclusively for existing partners? - Yes, the exploration partner access program is available only to partners within the OmniAb ecosystem [35] Question: What are the potential revenue opportunities from the exploration program? - Management indicated that while specific numbers are difficult to predict, early feedback from partners has been positive, and the program is expected to create new revenue streams [40][46] Question: How does the FDA's decision to move away from animal testing impact the business? - Management clarified that the FDA's announcement is separate from their offerings, but it could facilitate faster entry of antibody-based medicines into the clinic, which is seen as a potential benefit [68] Question: Will there be additional AI-driven platform offerings for customers? - Management confirmed that there are ongoing efforts to build out additional computational and AI-driven offerings, leveraging the data generated from the exploration platform [72]

[Music] My name is Dave Mooney. I'm the VP of worldwide data management sales at Lenovo Corporation. The challenges we help our customers overcome is to help them take an idea that they would like to drive and how they could enhance their business with AI and get it implemented first in experimentations and into fast starts all the way into full production.And we can do that from the pocket to the cloud and the data center. We but we're focusing on the enterprise customers. That's where we see the opportuni ...

Definitive Healthcare Corp. (NASDAQ:DH) Q4 2024 Results Conference Call February 27, 2025 5:00 PM ET Company Participants Matthew Ruderman - Investor Relations Kevin Coop - Chief Executive Officer Rick Booth - Chief Financial Officer Conference Call Participants Jared Haase - William Blair Hanna Lee - Bank of America Jenny Shen - BTIG David Grossman - Stifel Maxi Ma - Deutsche Bank Johnathan McCary - Raymond James Craig Hettenbach - Morgan Stanley Jeff Garro - Stephens Operator Welcome to Definitive Healthc ...